A phase I/II trial of temsirolimus plus neratinib for patients with metastatic HER2-amplified or triple-negative breast cancer
A phase I/II trial of temsirolimus plus neratinib for patients with metastatic HER2-amplified or triple-negative breast cancer
Sarat Chandarlapaty, MD, PhD (Memorial Sloan Kettering Cancer Center (MSKCC))